Telix [TLX] vs BridgeBio Pharma [BBIO] Detailed Stock Comparison
Telix
NASDAQ
Loading...
BridgeBio Pharma
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Telix wins in 7 metrics, BridgeBio Pharma wins in 9 metrics, with 0 ties. BridgeBio Pharma appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Telix | BridgeBio Pharma | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 133.20 | -16.03 | BridgeBio Pharma |
| Price-to-Book Ratio | 7.84 | -4.95 | BridgeBio Pharma |
| Debt-to-Equity Ratio | 102.33 | -1.04 | BridgeBio Pharma |
| PEG Ratio | N/A | -14.84 | N/A |
| EV/EBITDA | 48.65 | -15.52 | BridgeBio Pharma |
| Profit Margin (TTM) | 6.37% | 98.25% | BridgeBio Pharma |
| Operating Margin (TTM) | 8.46% | -120.72% | Telix |
| EBITDA Margin (TTM) | 8.46% | N/A | N/A |
| Return on Equity | 13.92% | 36.76% | BridgeBio Pharma |
| Return on Assets (TTM) | 5.33% | -41.96% | Telix |
| Free Cash Flow (TTM) | $9.00M | $-529.63M | Telix |
| 1-Year Return | -23.64% | 90.71% | BridgeBio Pharma |
| Price-to-Sales Ratio (TTM) | 5.69 | 36.81 | Telix |
| Enterprise Value | $2.76B | $9.68B | BridgeBio Pharma |
| EV/Revenue Ratio | 5.44 | 41.04 | Telix |
| Gross Profit Margin (TTM) | N/A | 96.70% | N/A |
| Revenue per Share (TTM) | $2 | $1 | Telix |
| Earnings per Share (Diluted) | $0.10 | $-4.13 | Telix |
| Beta (Stock Volatility) | 2.43 | 1.23 | BridgeBio Pharma |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Telix vs BridgeBio Pharma Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Telix | -3.74% | -13.10% | -27.72% | -33.49% | -37.31% | -24.40% |
| BridgeBio Pharma | 1.37% | -1.67% | 7.85% | 33.66% | 46.66% | 65.18% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Telix | -23.64% | -23.64% | -23.64% | -23.64% | -23.64% | -23.64% |
| BridgeBio Pharma | 90.71% | 301.64% | 63.30% | 72.75% | 72.75% | 72.75% |
Performance & Financial Health Analysis: Telix vs BridgeBio Pharma
| Metric | TLX | BBIO |
|---|---|---|
| Market Information | ||
| Market Cap | $4.46B | $8.68B |
| Market Cap Category | Mid cap | Mid cap |
| 10 Day Avg. Volume | 82,410 | 3,421,307 |
| 90 Day Avg. Volume | 59,260 | 3,093,596 |
| Last Close | $11.34 | $46.58 |
| 52 Week Range | $11.34 - $30.36 | $21.72 - $49.77 |
| % from 52W High | -62.65% | -6.41% |
| All-Time High | $30.36 (Feb 24, 2025) | $73.50 (Feb 08, 2021) |
| % from All-Time High | -62.65% | -36.63% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.49% | 50.00% |
| Quarterly Earnings Growth | 0.04% | 50.00% |
| Financial Health | ||
| Profit Margin (TTM) | 0.06% | 0.98% |
| Operating Margin (TTM) | 0.08% | -1.21% |
| Return on Equity (TTM) | 0.14% | 0.37% |
| Debt to Equity (MRQ) | 102.33 | -1.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.70 | $-9.35 |
| Cash per Share (MRQ) | $2.16 | $3.96 |
| Operating Cash Flow (TTM) | $27.86M | $-655,808,000 |
| Levered Free Cash Flow (TTM) | $47.14M | $-297,633,248 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Telix vs BridgeBio Pharma
| Metric | TLX | BBIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 133.20 | -16.03 |
| Forward P/E | 11.64 | -14.84 |
| PEG Ratio | N/A | -14.84 |
| Price to Sales (TTM) | 5.69 | 36.81 |
| Price to Book (MRQ) | 7.84 | -4.95 |
| Market Capitalization | ||
| Market Capitalization | $4.46B | $8.68B |
| Enterprise Value | $2.76B | $9.68B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.44 | 41.04 |
| Enterprise to EBITDA | 48.65 | -15.52 |
| Risk & Other Metrics | ||
| Beta | 2.43 | 1.23 |
| Book Value per Share (MRQ) | $1.70 | $-9.35 |
Financial Statements Comparison: Telix vs BridgeBio Pharma
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | TLX | BBIO |
|---|---|---|
| Revenue/Sales | N/A | $116.63M |
| Cost of Goods Sold | N/A | $2.64M |
| Gross Profit | N/A | $113.99M |
| Research & Development | N/A | $111.43M |
| Operating Income (EBIT) | N/A | $-103.80M |
| EBITDA | N/A | $-104.46M |
| Pre-Tax Income | N/A | $-169.61M |
| Income Tax | N/A | N/A |
| Net Income (Profit) | N/A | $-169.61M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | TLX | BBIO |
|---|---|---|
| Cash & Equivalents | $710.35M | $540.60M |
| Total Current Assets | $918.56M | $695.17M |
| Total Current Liabilities | $330.91M | $152.11M |
| Long-Term Debt | $559.96M | $1.85B |
| Total Shareholders Equity | $568.21M | $-1.64B |
| Retained Earnings | $-212.96M | $-3.26B |
| Property, Plant & Equipment | $0 | $13.86M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | TLX | BBIO |
|---|---|---|
| Operating Cash Flow | N/A | $-215.45M |
| Capital Expenditures | N/A | $0 |
| Free Cash Flow | $2.45M | $-200.83M |
| Debt Repayment | N/A | $-459.00M |
| Common Stock Repurchase | N/A | $-50.05M |
Short Interest & Institutional Ownership Analysis
| Metric | TLX | BBIO |
|---|---|---|
| Shares Short | 16,953 | 19.48M |
| Short Ratio | 0.33 | 5.61 |
| Short % of Float | 0.00% | 0.17% |
| Average Daily Volume (10 Day) | 82,410 | 3,421,307 |
| Average Daily Volume (90 Day) | 59,260 | 3,093,596 |
| Shares Outstanding | 334.72M | 190.04M |
| Float Shares | 268.22M | 149.71M |
| % Held by Insiders | 0.00% | 0.05% |
| % Held by Institutions | 0.00% | 0.96% |
Dividend Analysis & Yield Comparison: Telix vs BridgeBio Pharma
| Metric | TLX | BBIO |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |